AstraZeneca is advancing its investigational once-daily oral small-molecule GLP-1 receptor agonist, elecoglipron, into a broad Phase III programme after Phase IIb trials demonstrated up to 11.8% weight loss and a 1.9% reduction in HbA1c.
At the ADA 2026 Scientific Sessions, Novo Nordisk unveiled Phase 2 data for zenagamtide (amycretin), demonstrating exceptional blood sugar control and weight loss in type 2 diabetes.
Eli Lilly’s Retatrutide has demonstrated record-breaking efficacy in Phase 2 trials, showing that triple-hormone receptor agonists may be the future of chronic weight management.
Pfizer has initiated a pivotal Phase 3 study for its 25-valent pediatric pneumococcal vaccine (25vPnC) after Phase 2 data showed a 15-fold increase in immune response against serotype 3.
AbbVie presented late-breaking Phase 2 data at SGO 2026 showing that Mirvetuximab Soravtansine PSOC treatment combined with carboplatin achieved a 62.7% response rate in FRα-high patients, offering a new hope for platinum-sensitive recurrence.
Novo Nordisk and United Biotechnology announce that their jointly developed UBT251 triple agonist targeting GLP-1, GIP, and glucagon receptors outperformed semaglutide 1 mg in a 24-week Chinese phase 2 trial, setting the stage for global phase 3 development.
Atirmociclib Phase 2 data released mark a potentially defining moment in the treatment of hormone receptor-positive metastatic breast cancer. Pfizer’s investigational CDK4 inhibitor demonstrated a statistically [Read More…]
Pfizer’s investigational trispecific antibody, tilrekimig, met its primary endpoint in a Phase 2 study for atopic dermatitis, showing significant skin clearance and a favorable safety profile.
Roche’s investigational amylin analog, petrelintide, achieved a statistically significant 10.7% mean body weight reduction in a Phase II trial, offering a well-tolerated alternative to current obesity treatments.
Johnson & Johnson announces groundbreaking long-term clinical data revealing that TREMFYA (guselkumab) maintains sustained clinical, endoscopic, and histologic remission in adults with moderately to severely active ulcerative colitis through 3 years of treatment. The QUASAR long-term extension study demonstrates 80.8% clinical remission and 78.6% mucosal healing rates, setting new standards for inflammatory bowel disease management.
